NATALIE BLANCHARD: Open Payments
NPI 1265437438 · BROUSSARD, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,884 in 205 payments from 17 companies in 2025. Trend: 2023 $3,036 · 2024 $3,157 · 2025 $3,884
Food & beverage: $3,866Education: $19
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 24 | $638 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $497 |
| Otsuka America Pharmaceutical, Inc. | 20 | $384 |
| Janssen Pharmaceuticals, Inc | 10 | $314 |
| Alkermes, Inc. | 21 | $304 |
| ABBVIE INC. | 22 | $288 |
| Vanda Pharmaceuticals Inc. | 16 | $279 |
| Corium, LLC | 14 | $238 |
| Lundbeck LLC | 8 | $187 |
| Neurocrine BioSciences, Inc. | 11 | $181 |
Products named: Auvelity, REXULTI, CAPLYTA, ARISTADA, VRAYLAR, FANAPT, Azstarys, INVEGA SUSTENNA.
Industry payments across LA — which companies pay providers there.
